中国现代医生
中國現代醫生
중국현대의생
CHINA MODERN DOCTOR
2015年
2期
82-84
,共3页
替米沙坦%原发性高血压%心肌肥厚%左室舒张功能
替米沙坦%原髮性高血壓%心肌肥厚%左室舒張功能
체미사탄%원발성고혈압%심기비후%좌실서장공능
Telmisartan%Hypertension%Hypertrophy%Left ventricular diastolic function
目的：探讨替米沙坦对原发性高血压患者心肌肥厚及左室舒张功能的影响。方法选取我院2013年4月~2014年5月收治的78例原发性高血压并心肌肥厚及左室舒张功能不全患者为研究对象,均给予口服替米沙坦片方案,比对其治疗前后舒张压﹙DBP)、收缩压﹙SBP)变化情况及超声心动图各指标差异,记录其治疗前后心功能分级情况。结果淤治疗后,收缩压和舒张压分别为﹙107.6±9.9)mmHg和﹙73.3±5.2)mmHg,较治疗前的﹙153.5±12.6)mmHg和﹙98.9±8.0)mmHg降低,差异有统计学意义﹙P<0.05)；于治疗后,左心室后壁厚度、室间隔厚度、左心室舒末内径、左室重量指数、舒张晚期二尖瓣口血流速度峰值A等指标均较治疗前明显降低﹙P<0.05)；舒张早期二尖瓣口血流速度峰值E则显著升高﹙P<0.05)；盂治疗后,Ⅰ级例数由治疗前的24例增加至62例,心功能较治疗前明显改善﹙P<0.05)。结论对原发性高血压并心肌肥厚及左室舒张功能不全者予以口服替米沙坦方案,疗效显著,值得临床推广。
目的：探討替米沙坦對原髮性高血壓患者心肌肥厚及左室舒張功能的影響。方法選取我院2013年4月~2014年5月收治的78例原髮性高血壓併心肌肥厚及左室舒張功能不全患者為研究對象,均給予口服替米沙坦片方案,比對其治療前後舒張壓﹙DBP)、收縮壓﹙SBP)變化情況及超聲心動圖各指標差異,記錄其治療前後心功能分級情況。結果淤治療後,收縮壓和舒張壓分彆為﹙107.6±9.9)mmHg和﹙73.3±5.2)mmHg,較治療前的﹙153.5±12.6)mmHg和﹙98.9±8.0)mmHg降低,差異有統計學意義﹙P<0.05)；于治療後,左心室後壁厚度、室間隔厚度、左心室舒末內徑、左室重量指數、舒張晚期二尖瓣口血流速度峰值A等指標均較治療前明顯降低﹙P<0.05)；舒張早期二尖瓣口血流速度峰值E則顯著升高﹙P<0.05)；盂治療後,Ⅰ級例數由治療前的24例增加至62例,心功能較治療前明顯改善﹙P<0.05)。結論對原髮性高血壓併心肌肥厚及左室舒張功能不全者予以口服替米沙坦方案,療效顯著,值得臨床推廣。
목적：탐토체미사탄대원발성고혈압환자심기비후급좌실서장공능적영향。방법선취아원2013년4월~2014년5월수치적78례원발성고혈압병심기비후급좌실서장공능불전환자위연구대상,균급여구복체미사탄편방안,비대기치료전후서장압﹙DBP)、수축압﹙SBP)변화정황급초성심동도각지표차이,기록기치료전후심공능분급정황。결과어치료후,수축압화서장압분별위﹙107.6±9.9)mmHg화﹙73.3±5.2)mmHg,교치료전적﹙153.5±12.6)mmHg화﹙98.9±8.0)mmHg강저,차이유통계학의의﹙P<0.05)；우치료후,좌심실후벽후도、실간격후도、좌심실서말내경、좌실중량지수、서장만기이첨판구혈류속도봉치A등지표균교치료전명현강저﹙P<0.05)；서장조기이첨판구혈류속도봉치E칙현저승고﹙P<0.05)；우치료후,Ⅰ급례수유치료전적24례증가지62례,심공능교치료전명현개선﹙P<0.05)。결론대원발성고혈압병심기비후급좌실서장공능불전자여이구복체미사탄방안,료효현저,치득림상추엄。
Objective To investigate the effects of telmisartan in treatment of hypertrophy and diastolic function of left ventricular in patients with hypertension and left ventricular. Methods A total of 78 patients admitted to our hospital with primary hypertension and myocardial hypertrophy and left ventricular diastolic dysfunction from April 2013 to May 2014 were selected as the research objects, and they were given telmisartan tablets orally, the differences of diastolic blood pressure (DBP), systolic blood pressure (SBP) changes and the ultrasonic heartbeat of each index recorded before and after treatment, recorded the heart function classification as well were compared. Results ①After the treatment, systolic and diastolic blood pressure were (107.6±9.9) mmHg and (73.3±5.2) mmHg, compared with the data of before treatment (153.5±12.6) mmHg and(98.9±8.0) mmHg, decreased significantly and there were statistical differences(P<0.05); ②After the treatment, left ventricular posterior wall thickness, index interventricular septum thickness, left ven-tricular end diastolic diameter, left ventricular mass index and late diastolic mitral flow velocity A were significantly lower than that before treatment (P<0.05); Early diastolic mitral flow velocity peak E increased significantly (P<0.05);③After treatment, the number of grade Ⅰ from 24 patients before treatment increased to 62 cases, cardiac function significantly improved after treatment(P<0.05). Conclusion The significant effect on primary hypertension and myocar-dial hypertrophy and left ventricular diastolic dysfunction by oral telmisartan, is worth the clinical promotion.
